Newswire (Published: Monday, April 10, 2017, Received: Thursday, April 6, 2017, 2:23:01 PM CDT)

Word Count: 418

Reports Outline Prostate Cancer Study Findings from Wayne State University (Changing face of metastatic prostate cancer: the law of diminishing returns holds true)

By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on Oncology - Prostate Cancer is now available. According to news reporting originating in Detroit, Michigan, by NewsRx editors, the research stated, "Prostate cancer presents with a multitude of faces. It ranges from localized cancers staying quiescent for many years during active surveillance to the raging diffuse liver metastases causing terminal disease."

The news reporters obtained a quote from the research from Wayne State University, "The incidence of metastatic disease is increasing. This review will highlight some of the recent developments as well as ongoing challenges of managing advanced prostate cancer. Significant strides are being made in managing metastatic prostate cancer. With the evolution of multiple new therapies, now the optimal use of these therapies and their proper sequencing is being addressed. Research is ongoing for mapping out pathways of resistance to therapies and for discovering new targets. Genomic alterations and abnormalities in circulating tumor DNA are being detected and will hopefully lead us more toward biomarker based therapies. The next era in oncology belongs to immune therapy. However, in prostate cancer the immune checkpoint inhibitors have shown modest responses and a phase III trial of radiation therapy ? ipilimumab revealed no benefit. Efforts are ongoing with combination trials of enzalutamide and atezolizumab or pembrolizumab. PARP inhibitors are gradually being established for therapeutic purposes, with olaparib achieving breakthrough status for prostate cancer patients with BRCA1 and 2 and ATM mutations."

According to the news reporters, the research concluded: "The future will bring an era of personalized medicine in advanced prostate cancer as well as optimization and more strategic sequencing of existing therapies."

For more information on this research see: Changing face of metastatic prostate cancer: the law of diminishing returns holds true. Current Opinion In Oncology, 2017;():. (Lippincott Williams and Wilkins - www.lww.com; Current Opinion In Oncology - journals.lww.com/co-oncology/pages/default.aspx)

Our news correspondents report that additional information may be obtained by contacting U.N. Vaishampayan, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States (see also Oncology - Prostate Cancer).

Keywords for this news article include: Detroit, Michigan, Genetics, Oncology, Epidemiology, United States, Prostatic Neoplasms, North and Central America, Metastatic Prostate Cancer.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Wayne State University
Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.

Places

Central America
North America
United States
Americas
Michigan
Detroit

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Genetics
                  Genomics
            Medical Research
                  Personalized & Predictive Medicine Research